Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arcus Biosciences (RCUS) Interest & Investment Income (2018 - 2025)

Historic Interest & Investment Income for Arcus Biosciences (RCUS) over the last 8 years, with Q3 2025 value amounting to $10.0 million.

  • Arcus Biosciences' Interest & Investment Income fell 2857.14% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.0 million, marking a year-over-year decrease of 1568.63%. This contributed to the annual value of $52.0 million for FY2024, which is 2682.93% up from last year.
  • Arcus Biosciences' Interest & Investment Income amounted to $10.0 million in Q3 2025, which was down 2857.14% from $10.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Interest & Investment Income ranged from a high of $14.0 million in Q3 2024 and a low of $154000.0 during Q1 2021
  • For the 5-year period, Arcus Biosciences' Interest & Investment Income averaged around $7.5 million, with its median value being $9.0 million (2023).
  • As far as peak fluctuations go, Arcus Biosciences' Interest & Investment Income plummeted by 7619.78% in 2021, and later skyrocketed by 300559.01% in 2022.
  • Over the past 5 years, Arcus Biosciences' Interest & Investment Income (Quarter) stood at $519000.0 in 2021, then skyrocketed by 1441.43% to $8.0 million in 2022, then soared by 37.5% to $11.0 million in 2023, then grew by 9.09% to $12.0 million in 2024, then dropped by 16.67% to $10.0 million in 2025.
  • Its Interest & Investment Income stands at $10.0 million for Q3 2025, versus $10.0 million for Q2 2025 and $11.0 million for Q1 2025.